Work ability and quality of working life in atopic dermatitis patients treated with dupilumabAngela L. Bosma, Phyllis I. Spuls, Wouter Ouwerkerk et al.|The Journal of Dermatology|2021Cited by 13
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesAngela L. Bosma, Maritza A. Middelkamp‐Hup, Nick J. Reynolds et al.|JAAD International|2022Cited by 10
The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczemaEva Knöps, Louise A. A. Gerbens, Phyllis I. Spuls et al.|Trials|2024Cited by 6
Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registryAngelo Li, Phyllis I. Spuls, Annelie H. Musters et al.|British Journal of Dermatology|2024Cited by 3
A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocolElizaveta Gribaleva, Carsten Flohr, Niels Steen Krogh et al.|Skin Health and Disease|2025Cited by 1